company background image
RVNC logo

Revance Therapeutics NasdaqGM:RVNC Stock Report

Last Price

US$5.49

Market Cap

US$482.1m

7D

-1.3%

1Y

-83.9%

Updated

25 Feb, 2024

Data

Company Financials +

Revance Therapeutics, Inc.

NasdaqGM:RVNC Stock Report

Market Cap: US$482.1m

RVNC Stock Overview

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.

RVNC fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Revance Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Revance Therapeutics
Historical stock prices
Current Share PriceUS$5.49
52 Week HighUS$37.98
52 Week LowUS$5.00
Beta0.99
1 Month Change-7.89%
3 Month Change-20.43%
1 Year Change-83.91%
3 Year Change-79.09%
5 Year Change-67.95%
Change since IPO-79.55%

Recent News & Updates

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Dec 28
Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Recent updates

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Dec 28
Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Nov 10
Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Aug 10
Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Jun 14
Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Apr 17
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Jan 02
Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Revance Therapeutics submits sBLA for Daxxify for cervical dystonia

Oct 20

Revance climbs 14% as FDA approves facial injectable for frown lines

Sep 08

Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems

Aug 24

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Aug 04
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Revance: Potential Comeback On FDA Resubmission For DAXI

Jul 15

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Apr 17
Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Dec 27
Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Revance Therapeutics: Repricing Shares After A CRL

Oct 29

Is Revance Therapeutics (NASDAQ:RVNC) Using Debt In A Risky Way?

Sep 15
Is Revance Therapeutics (NASDAQ:RVNC) Using Debt In A Risky Way?

Revance Therapeutics: Frowning At The FDA

Aug 15

Shareholder Returns

RVNCUS PharmaceuticalsUS Market
7D-1.3%0.7%1.3%
1Y-83.9%24.0%25.6%

Return vs Industry: RVNC underperformed the US Pharmaceuticals industry which returned 24% over the past year.

Return vs Market: RVNC underperformed the US Market which returned 25.6% over the past year.

Price Volatility

Is RVNC's price volatile compared to industry and market?
RVNC volatility
RVNC Average Weekly Movement12.5%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: RVNC's share price has been volatile over the past 3 months.

Volatility Over Time: RVNC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1999534Mark Foleyhttps://www.revance.com

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX.

Revance Therapeutics, Inc. Fundamentals Summary

How do Revance Therapeutics's earnings and revenue compare to its market cap?
RVNC fundamental statistics
Market capUS$482.10m
Earnings (TTM)-US$414.24m
Revenue (TTM)US$214.16m

2.3x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RVNC income statement (TTM)
RevenueUS$214.16m
Cost of RevenueUS$175.94m
Gross ProfitUS$38.22m
Other ExpensesUS$452.46m
Earnings-US$414.24m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Feb 28, 2024

Earnings per share (EPS)-4.72
Gross Margin17.85%
Net Profit Margin-193.42%
Debt/Equity Ratio-403.3%

How did RVNC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.